目的 對2012-2016年西安市第一醫(yī)院質(zhì)子泵抑制劑（PPIs）的使用情況進行分析，為臨床合理用藥提供參考。方法 采用回顧性方法，對2012-2016年西安市第一醫(yī)院PPIs的銷售金額、用藥頻度（DDDs）、日均費用（DDC）和排序比（B/A）等進行統(tǒng)計分析。結果 2012-2016年，PPIs的銷售金額呈逐年增長的趨勢；門診和住院患者PPIs的銷售金額、DDDs整體呈增加趨勢；口服PPIs的銷售金額和DDDs分別占24.4%、71.3%；注射用PPIs的銷售金額和DDDs占比分別為75.6%、28.7%；5年來銷售金額排名前3位的是注射用泮托拉唑（40 mg）、注射用蘭索拉唑和雷貝拉唑鈉腸溶片；DDDs排名前3位的是蘭索拉唑腸溶片、雷貝拉唑鈉腸溶片和注射用泮托拉唑（40 mg）。奧美拉唑腸溶膠囊、蘭索拉唑腸溶片和泮托拉唑腸溶膠囊的DDC在5年中均小于10元。注射用蘭索拉唑和注射用泮托拉唑（40 mg）5年的B/A均小于1.00。消化科PPIs的用藥金額始終為第1位。結論 西安市第一醫(yī)院注射用泮托拉唑的用量相對較大，可能存在一定程度的過度用藥和不合理用藥。

Objective To analyze the application of proton pump inhibitors (PPIs) in Xi'an No. 1 Hospital from 2012 to 2016, and in order to provide reference for clinical rational use of drugs. Methods A retrospective survey was conducted to analyze consumption sum, frequency of drug use (DDDs), defined daily cost (DDC), and sequence ratio (B/A) of PPIs in Xi'an No. 1 Hospital from 2012 to 2016. Results Consumption sum of PPIs increased year by year from 2012 to 2016. Consumption sum and DDDs of outpatient and inpatient had a tendency of increase on the whole. Consumption sum and DDDs of oral PPIs accounted for 24.4% and 71.3%, while those of PPIs for injection accounted for 75.6% and 28.7%. The top three drugs in the list of consumption sum in 5 years were Pantoprazole for injection (40 mg), Lansoprazole for injection, and Rabeprazole Sodium Enteric-coated Tablets. DDDs of Lansoprazole Tablets, Pantoprazole for injection, and Rabeprazole Sodium Enteric-coated Tablets ranked top three. DDC of Omeprazole Enteric-coated Capsules, Lansoprazole Enteric-coated Tablets, and Pantoprazole Sodium Enteric-Coated Capsules in 5 years were lower than 10. B/A of Lansoprazole for injection and Pantoprazole for injection (40 mg) in 5 years were less than 1.00. Consumption sum of PPIs in Department of Gastroenterology ranked the first. Conclusion The usage of Lansoprazole for injection in Xi'an No. 1 Hospital is relatively large, and it may be some degree of excessive use and irrational use.